Myrtelle to Present Positive 6-month Post-Treatment Data in Its First- in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the National Tay-Sachs and Allied Diseases Annual Family Conference
Wakefield, Mass., Wednesday, May 31, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
May 31, 2023
This article is featured on another website.
Go to article
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…
May 1, 2026
Headed to ASCO 2026? Meet the HiRO Team in Chicago
HiRO will be Attending the ASCO Annual Meeting: Advancing Oncology Innovation | Visit Us at…
May 1, 2026
Headed to ASCO 2026? Meet the HiRO Team in Chicago
HiRO will be Attending the ASCO Annual Meeting: Advancing Oncology Innovation | Visit Us at…